Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 4, 2016. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMR) and persons closely associated with them (PCA).
Key Financial Metrics
This filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports specific share transaction details:
- Instrument: GlaxoSmithKline plc American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Price: $38.74 per ADS.
- Total Volume Reported: 25 ADSs (22 ADSs for Dr. M M Slaoui; 3 ADSs for Dr. K Slaoui).
Material Changes
The filing reports no material changes to the company's financial position or operations. The reported changes are limited to the increase in shareholdings for two individuals due to the notional allocation of ADSs within the GSK 401(K) plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions described were automatic revaluations of cash elements held within a retirement plan, not discretionary trades.
Key Facts for Investor Verification
- Dr. M M Slaoui (Chairman, Global Vaccines) acquired 22 ADSs on November 3, 2016.
- Dr. K Slaoui (PCA of Dr. M M Slaoui) acquired 3 ADSs on November 3, 2016.
- Both transactions occurred at a price of $38.74 per ADS.
- The acquisitions resulted from the revaluation of cash elements in the GSK 401(K) plan, not open market purchases.